Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is a standard first-line systemic therapy in advanced hepatocellular carcinoma (aHCC) and is widely used in all lines. However, the efficacy and safety of immune checkpoint inhibitors (ICIs) plus molecular targeted agents (MTAs) after the progression of lenvatinib treatment ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Fucun, Chen, Bowen, Yang, Xu, Wang, Huaiyuan, Zhang, Ge, Wang, Yanyu, Wang, Yunchao, Zhang, Nan, Xue, Jingnan, Long, Junyu, Li, Yiran, Sun, Huishan, Xun, Ziyu, Liu, Kai, Chen, Xiangqi, Song, Yang, Yang, Xiaobo, Lu, Zhenhui, Mao, Yilei, Sang, Xinting, Lu, Yinying, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780480/
https://www.ncbi.nlm.nih.gov/pubmed/36569829
http://dx.doi.org/10.3389/fimmu.2022.1052937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780480/
https://www.ncbi.nlm.nih.gov/pubmed/36569829
http://dx.doi.org/10.3389/fimmu.2022.1052937

Ejemplares similares